Collegium Pharmaceutical (COLL) Expected to Announce Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $1.54 per share and revenue of $179.68 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Collegium Pharmaceutical Stock Up 0.7 %

Shares of Collegium Pharmaceutical stock opened at $29.91 on Thursday. The business has a 50-day moving average of $31.01 and a 200-day moving average of $33.75. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market capitalization of $964.60 million, a PE ratio of 12.89 and a beta of 0.82. Collegium Pharmaceutical has a 1-year low of $28.39 and a 1-year high of $42.29.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 3.98% of the company’s stock.

Analyst Ratings Changes

COLL has been the subject of several recent analyst reports. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Piper Sandler lowered their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.